ConDrug is a cornerstone of Aurealcraft Inc.’s growth plan—our focused bet to set the global standard for AI-assisted pharmacovigilance and evidence generation.

1) Product Strategy — “Minutes to Decision”

• Outcome-first workflows: Reduce time from label-to-signal to minutes with explainable AI, cited sources, and reproducible pipelines.
• Audit-ready by default: Versioned datasets (1939–present), change logs, and branded PDF/CSV exports that withstand inspection.
• Interoperable core: Open APIs, batch jobs, and connectors for CRO/biotech toolchains—no lock-in.
• Roadmap cadence: Ship weekly improvements; quarterly “anchor” features (batch signal review, uncertainty metrics, collaborative review rooms).

2) Data & AI Advantage — Durable Moats

• Continuously refreshed data fabric: Normalized labels/NDCs/documents updated daily with lineage and quality checks.
• Explainable AI: Model rationales, confidence bands, and human-in-the-loop review for critical calls.
• Learning from safe signals: Aggregated/De-identified telemetry improves ranking, recall, and speed—without using Customer Data to train unrelated third-party models.
• Validation loop: Public benchmarks and customer acceptance tests to keep models honest.

3) Go-to-Market — Land, Prove, Expand

• ICP focus: CROs, mid-size biotechs, and MAH/generics where throughput and audit readiness are acute needs.
• Entry motion: Self-serve trials and short demos that prove “minutes to decision.”
• Pricing that scales with value: Starter (individuals) and Growth (teams) with credits/overage; Enterprise for SSO/SLA/validation.
• Multi-channel acquisition: Email + LinkedIn for reach, partner-led for credibility, webinars and case briefs for proof.
• Customer success as a profit center: Playbooks to lift trial→paid and expand seats/usage within 90 days.

4) Partnerships — Distribution & Credibility

• CRO alliances: Embed ConDrug into routine safety reviews; revenue sharing and reference programs.
• Domain advisors & KOLs: Methodology reviews, benchmark co-design, and conference visibility.
• Regulatory dialogue: Transparent methods and auditable outputs to align with evolving expectations.

5) Trust, Security, and Compliance — License to Operate

• Security by design: Encryption, least privilege, monitoring, and disciplined incident response.
• Privacy rules: No PHI without BAA; regional safeguards for cross-border transfers; clear DPAs and subprocessors.
• Quality posture: Documented pipelines, reproducible runs, and optional validation packages for regulated environments.

6) Unit Economics — Efficient, Defensible Growth

• High gross margin SaaS: Compute/IO tightly managed; heavy operations priced via credits/overage.
• Healthy payback: LTV/CAC ≥ 3 with ≤ 6-month payback; annual prepay to improve cash conversion.
• Expansion engine: Seat growth, batch modules, and compliance add-ons.

7) International Expansion — Methodical, Compliant

• Phase 1: U.S. and EU5 CRO/biotech clusters; English-first workflows.
• Phase 2: Localization, regional hosting options, and targeted partnerships in high-density PV markets.
• Standards alignment: Interop with PV/RA ecosystems to reduce onboarding friction.

8) Operating System — Measure What Matters

• North-star metrics: Time-to-insight, analyst throughput uplift, audit acceptance without rework.
• Business KPIs: MRR/ARR, gross margin, CAC, LTV, churn, and expansion revenue.
• Quality KPIs: Model accuracy/latency dashboards, data freshness, and incident MTTR.

---

What this delivers: Faster, defensible safety decisions for customers; a compounding data-and-workflow moat for Aurealcraft; and a scalable, margin-rich business with ConDrug at the center of our long-term growth.